We are live on ! Find out more
TRIL

Trillium Therapeutics Inc.
TRIL

Delisted

TRIL was delisted on the 16th of November, 2021.

Back to rankings

29 hedge funds and large institutions have $14.9M invested in Trillium Therapeutics Inc. in 2016 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 11 increasing their positions, 5 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

120% more repeat investments, than reductions

Existing positions increased: 11 | Existing positions reduced: 5

9% less funds holding

Funds holding: 32 → 29 (-3)

23% less first-time investments, than exits

New positions opened: 10 | Existing positions closed: 13

71% less capital invested

Capital invested by funds: $51.3M → $14.9M (-$36.3M)

Holders
29
Holders Change
-3
Holders Change %
-9.38%
% of All Funds
0.72%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
10
Increased
11
Reduced
5
Closed
13
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
SAM
Sectoral Asset Management
Quebec, Canada
+$996K
2
Victory Capital Management
Victory Capital Management
Texas
+$552K
3
CS
Credit Suisse
Switzerland
+$253K
4
PCM
Prelude Capital Management
New York
+$230K
5
VKH
Virtu KCG Holdings
New York
+$224K

Top Sellers

Rank Fund Capital Flow
1
Point72 Asset Management
Point72 Asset Management
Connecticut
-$5.46M
2
EAM
EverPoint Asset Management
Connecticut
-$4.43M
3
DM
Deerfield Management
New York
-$2.55M
4
PCA
Private Capital Advisors
Connecticut
-$2.17M
5
SFM
Sphera Funds Management
Israel
-$1.96M
Name Holding Trade Value Shares
Change 		Change in
Stake
JHIU
1
Janus Henderson Investors US
Colorado
$3.23M +$16.1K +1,619 +0.3%
BBA
2
Baker Bros. Advisors
New York
$2.34M – – –
Franklin Resources
3
Franklin Resources
California
$2.23M – – –
ACA
4
Avoro Capital Advisors
New York
$1.28M -$882K -88,621 -28%
IBT
5
International Biotechnology Trust
United Kingdom
$1.25M +$2.21M +221,847 New
CS
6
Candriam SCA
Luxembourg
$624K – – –
OM
7
Opaleye Management
Massachusetts
$622K -$647K -65,000 -37%
SAM
8
Sectoral Asset Management
Quebec, Canada
$565K +$996K +100,000 New
NLVP
9
New Leaf Venture Partners
New York
$547K +$159K +16,000 +20%
PI
10
Putnam Investments
Massachusetts
$470K -$168K -16,889 -17%
Victory Capital Management
11
Victory Capital Management
Texas
$313K +$552K +55,430 New
Creative Planning
12
Creative Planning
Kansas
$147K +$179K +18,000 +222%
CS
13
Credit Suisse
Switzerland
$143K +$253K +25,382 New
OAM
14
Oxford Asset Management
United Kingdom
$139K +$79.3K +7,967 +48%
PCM
15
Prelude Capital Management
New York
$133K +$230K +23,100 +5,775%
VKH
16
Virtu KCG Holdings
New York
$127K +$224K +22,470 New
SSA
17
Schonfeld Strategic Advisors
New York
$125K +$20.4K +2,047 +10%
Jane Street
18
Jane Street
New York
$109K +$191K +19,230 New
KPF
19
K2 Principal Fund
Ontario, Canada
$92K +$162K +16,239 New
Bank of America
20
Bank of America
North Carolina
$89K +$153K +15,400 +3,850%
TI
21
Trexquant Investment
Connecticut
$84K +$148K +14,902 New
Millennium Management
22
Millennium Management
New York
$81K -$29K -2,910 -17%
Wells Fargo
23
Wells Fargo
California
$75K +$13.9K +1,400 +12%
TC
24
TFS Capital
Pennsylvania
$58K +$102K +10,247 New
Deutsche Bank
25
Deutsche Bank
Germany
$34K +$15.2K +1,523 +33%
1
2

TRIL Hedge Fund Activity: Q4 2016 in Review

29 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in Trillium Therapeutics Inc. (TRIL) for Q4 2016, worth a combined $14.9M — down 71% from $51.3M a quarter earlier.

Sellers outnumbered buyers: 13 funds closed out of TRIL and 10 opened new positions — a net loss of 3 holders — while 5 trimmed existing stakes and 11 added.

The largest buyer was Sectoral Asset Management, opening a new position worth an estimated $996K. The largest seller was Point72 Asset Management, exiting entirely with an estimated $5.46M sold.

  • 29 institutional investors held Trillium Therapeutics Inc. (TRIL) as of Q4 2016, down from 32 in Q3 2016.
  • Funds reported $14.9M of Trillium Therapeutics Inc. stock for Q4 2016, down 71% quarter-over-quarter.
  • 10 funds opened new Trillium Therapeutics Inc. positions in Q4 2016 and 13 closed out, a net change of -3 holders.
  • The largest Trillium Therapeutics Inc. buyer in Q4 2016 was Sectoral Asset Management, an estimated $996K added.
  • The largest Trillium Therapeutics Inc. seller in Q4 2016 was Point72 Asset Management, an estimated $5.46M sold.

Based on aggregated 13F filings for Q4 2016.